Table 1.
Patient Population (176 subjects followed for at least 90 days).
| All subjects N |
Subjects with AF>30 sec N |
|||
|---|---|---|---|---|
| Age (years) | 176 | 65.4 (26–89) | 49 | 67.9 (35–88) |
| Gender (male) | 123 (70%) | 33 (67%) | ||
| Race | ||||
| White | 164 (93%) | 47 (96%) | ||
| Black | 8 (5%) | 2 (4%) | ||
| Other | 4 (2%) | 0 (0%) | ||
| BMI (kg/m2) | 158 | 29.0 (16–57) | 40 | 27.8 (19–45) |
| Structural heart disease | 176 | 49 | ||
| Ischemic | 91 (52%) | 30 (61%) | ||
| Nonischemic | 52 (30%) | 10 (20%) | ||
| Other | 33 (19%) | 9 (18%) | ||
| Left ventricular ejection fraction (%) | 174 | 31.4 (10–70) | 49 | 31.4 (10–70) |
| History of revascularization | ||||
| CABG | 175 | 45 (26%) | 49 | 15 (31%) |
| PCI | 176 | 29 (17%) | 49 | 13 (27%)* |
| History of congestive heart failure | 176 | 96 (55%) | 49 | 31 (63%) |
| CHF class I | 19 (11%) | 8 (16%) | ||
| II | 31 (18%) | 10 (20%) | ||
| III | 46 (26%) | 13 (27%) | ||
| IV | 0 | 0 | ||
| Indications for implant | 176 | 49 | ||
| Primary prophylaxis | 111 (63%) | 31 (63%) | ||
| Secondary (cardiac arrest or sustained VT) | 33 (19%) | 7 (14%) | ||
| Syncope apparently arrhythmic | 32 (18%) | 11 (23%) | ||
| Co-morbidities | ||||
| Pulmonary Disease | 176 | 31 (18%) | 49 | 13 (27%) |
| Diabetes | 174 | 47 (27%) | 49 | 13 (27%) |
| Hypertension | 172 | 98 (57%) | 48 | 27 (56%) |
| History of AF | 175 | 51 (29%) | 49 | 24 (49%)* |
| Medications | 170 | 47 | ||
| ACE-I or ARB | 142 (84%) | 41 (87%) | ||
| Beta blocker | 158 (93%) | 43 (91%) | ||
| Antiarrhythmic agents: (Amiodarone, sotalol, or others not including beta blockers) | 28 (17%) | 10 (21%) | ||
| Platelet Aggregation Inhibitors | 115 (68%) | 31 (66%) | ||
| Statin | 123 (72%) | 38 (81%) | ||
| Smoking | ||||
| Current | 175 | 24 (14%) | 49 | 5 (11%) |
| Former | 175 | 85 (49%) | 49 | 25 (51%) |
| Never | 175 | 66 (38%) | 49 | 19 (39%) |
| Lived with Smoker | 175 | 111 (64%) | 49 | 32 (65%) |
| History of sleep apnea | 169 | 25 (15%) | 45 | 7 (16%) |
*
P< 0.05 between those with and without atrial fibrillation in follow-up.